Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Capitalizes On Patent Expiry To Launch First Perforomist Rival

Analyst Projects Financial Hit For Originator Viatris

Executive Summary

Teva has added to its vast portfolio in the US by introducing the first generic version of Viatris’ Perforomist for chronic obstructive pulmonary disease, as well as a generic of Soolantra to treat rosacea.

You may also be interested in...



Viatris Promises Clarity And Certainty On $9bn Transformation Plans

Confident that it will divest all non-core assets by the end of next year, Viatris says it understands “the importance of remaining engaged” with investors during the revamp. Meanwhile, the company is keeping a close eye on foreign exchange rate headwinds moving further into 2022, while electing not to row back further on its 2022 full-year guidance.

Viatris Wins First US Symbicort Generic – Will It Launch At Risk?

In the wake of a favorable US Court of Appeals for the Federal Circuit decision, Viatris has won FDA approval for the first generic Symbicort product. The ANDA sponsor’s management had recently declared itself “ready to launch if the opportunity presents itself in 2022.”

Teva Leapfrogs Taro With Authorized Generic Epiduo Forte Launch

Teva has added another major dermatology brand to its armory, with the launch of an authorized generic version of Galderma’s Epiduo Forte Gel.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151032

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel